The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Open-label phase II clinical trial of orteronel (TAK-700) in metastatic or advanced nonresectable granulosa cell ovarian tumors: The GREKO II study.
Alicia Hurtado
No relevant relationships to disclose
Jesús García-Donas
No relevant relationships to disclose
Laia Garrigos
No relevant relationships to disclose
Nuria Laínez
No relevant relationships to disclose
Andres Redondo
No relevant relationships to disclose
Juan Fernando Cueva
No relevant relationships to disclose
Ana Santaballa
No relevant relationships to disclose
Maria Jesus Rubio
No relevant relationships to disclose
Isabel Palacio
No relevant relationships to disclose
Isabel Bover
No relevant relationships to disclose
Jose Antonio Lopez-Guerrero
No relevant relationships to disclose
Mario Prieto
No relevant relationships to disclose
Zaida Garcia-Casado
No relevant relationships to disclose
Susana Hernando Polo
No relevant relationships to disclose
Nuria Romero
No relevant relationships to disclose
Enrique Grande
No relevant relationships to disclose